The world's largest pharmaceutical market access conference
Pharma Pricing & Market Access Outlook Europe - list of sponsors & exhibitors
ZS Associates is a global leader in sales and marketing consulting, outsourcing, technology and software. The firm has more than 1,900 professionals in 20 offices around the world, and has assisted more than 700 clients in 70 countries. ZS...
GalbraithWight® Market Access will add significant value to your work because we provide precisely the support you need at every stage of the process to achieve successful Market Access. Our leading edge work has pioneered the understanding and...
UBC is a global pharmaceutical services organization that combines deep scientific knowledge with broad operational expertise to meet the growing demands for strategic execution of post approval programs.
Our focus is on generating real-world data ...
Bridgehead International is a leading biopharmaceutical consultancy group, offering a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain.
Our mission is to work with...
Innovus is now OptumInsight—part of Optum, a leading health services business. OptumInsight provides an expert perspective on global market requirements to help companies make strategic decisions about their products. With leading expertise in...
PDCI Market Access Inc. (PDCI) a leading pricing and reimbursement consultancy with services that combine a global perspective with local market expertise.
Based in Ottawa, PDCI provides comprehensive market access services for the Canadian market ...
Applied Policy is the go-to firm for navigating U.S. health reform implementation, the Centers for Medicare & Medicaid Services and other agencies of the U.S. Department of Health and Human Services.
We regularly work with pharmaceutical...
Medaxial is a specialist value communication consultancy with more than 15 years’ experience of serving the global healthcare industry. The services we offer are based on two core beliefs: First, that no activity is more important to innovative...